TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06326593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii aerobic training
Description: Nintendo Wii Fit Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conservative chest care
Description: Diaphragmatic deep breathing exercises Bronchial hygiene techniques Assisted cough Stretching exercises and ROM exercises for both upper and lower limbs
Study: NCT03222726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise group
Description: less than 6000 steps/day or 40,000 steps/week
Study: NCT05200065

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thulium laser enucleation of the prostate
Description: Using the thulium laser to achieve complete endoscopic enucleation of the prostate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar enucleation of the prostate
Description: Using the bipolar plasma energy to achieve complete endoscopic enucleation of the prostate.
Study: NCT06326593

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conservative chest care
Description: Diaphragmatic deep breathing exercises Bronchial hygiene techniques Assisted cough Stretching exercises and ROM exercises for both upper and lower limbs
Study: NCT04490200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VESTA respirator
Description: The protocol will be composed by the use of the VESTA respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional N95 respirator
Description: The protocol will be composed by the use of the N95 respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
Study: NCT04120636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Episcleral Celecoxib
Description: Sustained Release Transscleral Celecoxib
Study: NCT05084469

Intervention type: PROCEDURE
Intervention: PET-MRI in pain-free remission period
Description: Patients will performed PET-MRI scans. A first 30 minutes acquisition will be performed at time=60min after injection. A second 75 minutes acquisition will be performed at time=150min. Each scans will contain functional dynamic \[18F\]F13640 PET acquisition, anatomical and functional MRI images acquisition and pain evaluation using a score visual analogic scale.
Study: NCT06143969

Intervention type: PROCEDURE
Intervention: ultrasound-assisted, catheter-directed thrombolysis
Description: After 10 hours of alteplase infusion and EKOSTM ultrasound, the therapy is stopped, the EKOSTM catheter is removed, and the puncture site (internal jugular vein or femoral vein) has to be compressed.
Study: NCT05406167

Intervention type: DEVICE
Intervention: Registry - Observational
Description: Observation Registry for Medical Device

Intervention type: DEVICE
Intervention: Registry - Observational
Description: Observation Registry for Medical Device

Intervention type: DEVICE
Intervention: Registry - Observational
Description: Observation Registry for Medical Device
Study: NCT06147908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW5221
Description: megestrol acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW5221
Description: megestrol acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW5221-R
Description: megestrol acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW5221-R
Description: megestrol acetate
Study: NCT05101967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Cervical Implant
Description: Cervical discectomy through anterior approach with replacement of disc by dynamic implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomt and Fusion
Description: Cervical discectomy through anterior approach with putting of cervical cage.
Study: NCT04318847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 MG
Description: Administration of ondansetron 4 mg or 8 mg according to weight
Study: NCT05769647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: 3 minutes after the individual starts watching the video, the IV catheter insertion attempt will be performed while continuing to watch the video.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: Patients will be given a ball and instructed to tighten and loosen with their free hand during IVC placement. The patient will continue to squeeze the ball throughout the IV catheter insertion attempt.
Study: NCT04723602

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cAd3-Marburg
Description: A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10\^11 Particle Units (PU) vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cAd3-EBO-S
Description: A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10\^11 Particle Units (PU) vaccine.
Study: NCT05664464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Weekly dose escalations over 4 weeks of daily 3 x 300 mg up to 3 x 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Weekly dose escalations over 3 weeks of daily 3 x 500 mg up to 3 x 1500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Weekly dose escalations over 4 weeks of daily 1 x 5-20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Concomitant with radiotherapy at 75 mg/m2 daily followed by maintenance 150-200 mg/m2 on 5/28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concomitant with radiotherapy at 75 mg/m2 daily followed by maintenance 150-200 mg/m2 on 5/28 days

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 30 x 2 Gy involved field radiotherapy with concomitant temozolomide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 30 x 2 Gy involved field radiotherapy with concomitant temozolomide
Study: NCT06170268

Intervention type: OTHER
Intervention: Routine Care Documentation
Description: Routine Care Documentation
Study: NCT05240677

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Upper GIT endoscopy
Description: Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper GIT endoscopy
Description: Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions
Study: NCT04875065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage coaching
Description: Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands.
Study: NCT05432713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-168 tablet
Description: Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LP-168 Placebo tablet
Description: LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets
Study: NCT06147999

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Biophotonizer - a Biophoton Generator
Description: A biophotonizer is a device producing strong biophoton field. These biophotons help the human body to gain self-healing capacity to heal many disorders, including brain disorders.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biophotonizer - a Biophoton Generator
Description: A biophotonizer is a device producing strong biophoton field. These biophotons help the human body to gain self-healing capacity to heal many disorders, including brain disorders.
Study: NCT06248333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN-DBS ON
Description: Stimulation ON

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: STN-DBS OFF
Description: Stimulation OFF
Study: NCT04428372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Hypertonic mannitol infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Normal saline 'placebo' arm
Study: NCT04871425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: IV fentanyl
Study: NCT05167435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Experimental
Description: Myofascial release is a gentle sustained pressure that elongates fascial adhesions so that tissue can return to proper realignment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior-Anterior Glide
Description: Posterior-anterior mobilization is a standard assessment and treatment technique for most clinicians. It is a mobilization technique that involves passive oscillatory movements applied to a vertebral segment in a posteroanterior direction (Back to front).
Study: NCT05195567

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucometer Test
Description: measurement of the blood glucose concentration using the blood glucose monitor for personal use

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement, laboratory reference device
Description: measurement of the blood glucose concentration using a laboratory reference device
Study: NCT05068258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphovenous bypass, including lymphaticovenular anastomosis/implantation
Description: Lymphovenous bypass (LVB) is a supermicrosurgical technique by diverting lymphatic drainage into venous system. Simultaneously, we performed LVB at ipsilateral foot dorsum and debride the VLUs and resurface the wound primarily or by skin graft depending on defect size.
Study: NCT03222726

Intervention type: OTHER
Group type: OTHER
Intervention: exercise group
Description: less than 6000 steps/day or 40,000 steps/week
Study: NCT04167813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg or matched placebo tablets
Description: Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase
Study: NCT05598671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCNL without reverse insertion of a ureteral catheter
Description: The ureteral catheter was not retrograde inserted during PCNL
Study: NCT04167813

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 8mg or matched placebo tablets
Description: Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase
Study: NCT05529693

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Bif-038 arm, high dose
Description: Active trial product with minimum 10 billion CFU daily dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Bif-038 arm, low dose
Description: Active trial product with minimum 1 billion CFU daily dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo arm
Description: Similar product to trial product but without Bif-038
Study: NCT04242251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARKLE Model of care
Description: Patients will receive the SPARKLE model of care in addition to usual oncologist-led care. The SPARKLE model will be led by a palliative medicine doctor and administered by nurses and staff without specific nursing or medical training. It utilizes a stepped care approach where all patients will initially have low-intensity model focused on weekly symptom monitoring through a patient-reported questionnaire. If any problems are identified, then patients step up to a higher-intensity care model where a nurse will conduct a phone assessment of the symptom problems. If the presence of symptoms is confirmed, patients step up again to an even higher-intensity care model where treatment of symptoms will be initiated by the SPARKLE nurse, depending on the severity of the problems. If the symptoms are not fully resolved, the patients will then step up to the highest-intensity care model which is an existing palliative care service- either palliative care outpatient clinic or home hospice.
Study: NCT05478239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ArtemiCoffee
Description: 3 cups of Artemisia annua (Aa) coffee per day (1350mg) for 24 weeks.
Study: NCT05668910

Intervention type: GENETIC
Intervention: whole genomic methylation and fragmentation profile analysis of cfDNA
Description: The assay for gastric cancer early detection will be built based on low-depth methylone sequencing followed with a multi-dimensional model construction with analysing several features such as methylation, fragmentation, and chromosomal copy number alternation.

Intervention type: GENETIC
Intervention: whole genomic methylation and fragmentation profile analysis of cfDNA
Description: The assay for gastric cancer early detection will be built based on low-depth methylone sequencing followed with a multi-dimensional model construction with analysing several features such as methylation, fragmentation, and chromosomal copy number alternation.
Study: NCT02859714

Intervention type: OTHER
Intervention: screening data
Study: NCT05851053

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: During echocardiography, the following parameters will be assessed:~* Dimensions~* Left ventricle function~* Right ventricle function~* Valves: Aorta valve and pulmonic valve~* Other findings such as: frequency, rhythm, quality

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: During echocardiography, the following parameters will be assessed:~* Dimensions~* Left ventricle function~* Right ventricle function~* Valves: Aorta valve and pulmonic valve~* Other findings such as: frequency, rhythm, quality
Study: NCT04540887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field (PEMF) Therapy
Description: PEMF therapy will be self-administered by all trial participants using the B. Body, B. Pad, and Control Unit. Participants will administer this therapy twice a day (morning and evening) for 8-minute sessions over a four week period.
Study: NCT04831151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: Yasmin: 0,03 mg ethinylestradiol + 3 mg drospirenone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diane-35
Description: Diane 35: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate
Study: NCT05586139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiome-directed food - MAM
Description: Each MAM child will be supplemented with MDF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
Study: NCT05874024

Intervention type: PROCEDURE
Intervention: induction of labour with double balloon catheter placement for 6 hours
Description: catheter placement for 6 hours beginning in the morning at around 8 a.m.

Intervention type: PROCEDURE
Intervention: induction of labour with double balloon catheter placement for 12 hours
Description: catheter placement for 12 hours in the evening at around 8 p.m.
Study: NCT05724745

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 1. Standard spirometry
Description: Spirometry is performed in two positions (sitting and supine) and three types of breathing (spontaneous, forced and slow).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 2. 3D dynamic lung MRI at UTE in prone and supine positions
Description: Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine before a reversibility test with salbutamol.

Intervention type: DRUG
Group type: OTHER
Intervention: 3. Reversibility test with salbutamol
Description: Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
Study: NCT06067919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decision tree for the choice of intraoperative antibiotic prophylaxis
Description: Presentation of a decision tree to anaesthetists to guide the choice of intraoperative antibiotic prophylaxis
Study: NCT05724745

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 4. 3D dynamic lung MRI at UTE in supine and prone position
Description: Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine after the bronchodilatator's administration.
Study: NCT05586139

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-use supplementary food (RUSF)
Description: Each MAM child will be supplemented with RUSF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
Study: NCT05849805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracalvaria bone marrow injection
Description: Intracalvaria bone marrow injection Y-3 (dose was given at 32 ug/kg), continuous medication for 3 days

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: standard treatment and management according to related guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: standard treatment and management according to related guidelines
Study: NCT04802434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengthening Skills Program
Description: The Strengthening Skills Program is a new, multi-component intervention. It includes three components: (1) Forming habits to compensate for the difficulties many adults with ASD have with thinking flexibly, planning, and time management. It will emphasize habit-forming behaviors to compensate for weaknesses in functional skills by training on practical techniques; (2) Content from the PEERS Social Skills program to target social challenges, and (3) strategies derived from Mindfulness Based Stress Reduction to target emotion regulation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PEERS Social Skills Program
Description: PEERS® is a well-established social communication training program, initially developed for adolescents, and more recently extended to young adults with ASD. Program content will be adapted slightly so as to be appropriate for older adults.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS Social Skills Program
Description: PEERS® is a well-established social communication training program, initially developed for adolescents, and more recently extended to young adults with ASD. Program content will be adapted slightly so as to be appropriate for older adults.
Study: NCT05586139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiome-directed food (MDF) - SAM
Description: Each SAM child will be supplemented with MDF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-use therapeutic food (RUTF)
Description: Each SAM child will be supplemented with RUTF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
Study: NCT04596293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-401-1S or Placebo
Description: Administered by 200mg capsules of BBT-401-1S or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-401-1S or Placebo
Description: Administered by 200mg capsules of BBT-401-1S or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BBT-401-1S or Placebo
Description: Administered by 200mg capsules of BBT-401-1S or placebo
Study: NCT05903352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop antibiotic
Description: Stop the antibiotic treatment on day S (stability criteria reached for 24 h or within 48 hours after the start of antibiotic treatment).